FDA approves Rapivab for treatment of Influenza- Biocryst Pharma
BioCryst Pharmaceuticals, Inc. announced that the FDA has approved Rapivab (peramivir injection), an intravenous (i.v.) neuraminidase inhibitor for the treatment of acute uncomplicated Influenza in patients 18 years and older who have been symptomatic for no more than two days. Rapivab's approval was supported by data from over 2,700 subjects treated with peramivir in 27 clinical trials.
In January 2010, Shionogi & Co., Ltd. launched intravenous peramivir in Japan under the name Rapiacta and in August 2010, Green Cross Corporation announced that it had received marketing and manufacturing authorization for i.v. peramivir in Korea under the name PeramiFlu. It is estimated that more than one million patients have received peramivir treatment to date.
Learning Zones
The Learning Zones are an educational resource for healthcare professionals that provide medical information on the epidemiology, pathophysiology and burden of disease, as well as diagnostic techniques and treatment regimens.
1 mins